Comedian and Australian native Jim Jefferies is one of the most popular comedians of his generation, entertaining audiences with his provocative, belief-challenging and thought-provoking comedy.

Tickets are $23 in advance, via LiveNation, and $25 on the day of show. The Australian-born comedian Jim Jefferies has been performing for more than 20 years, with nine stand-up specials ...

The Broncos won the game 24 – 20. (Photo by Earl Richardson/Allsport/Getty Images) Acclaimed broadcaster and beloved Chiefs player, Bill Mass joins Jim Bob Morris and Dane Neal on WGN Radio. Hear as ...

But I must admit, I'm also a little bit … sad. You may wonder, "Jim, are you sad because your team didn't make it?" No, it's not that. Is it because the Lions and the Bills couldn't complete ...

We recently published an article titled Jim Cramer Discussed 9 Stocks for This Week's Game Plan. In this article, we are going to take a look at where 3M Company (NYSE:MMM) stands against the ...

The Village People are not a fan of Aussie comedian Jim Jefferies, it seems. Or at the very least, they’re not a fan of how he’s characterised one of their biggest songs, Y.M.C.A.

The Magnificent Seven stocks have been a huge source of gains for the S&P 500. Without the cohort of tech titans, I think it’ll be tough for the broad market to top 20% returns for a third ...

Jefferies said that all seven companies outperformed the S&P 500 over the past five years, but the performance of the companies was quite different based on the factors examined.

We recently published an article titled Jim Cramer Discussed 9 Stocks for This ... 3M reports in the morning, and I bet that CEO Bill Brown, he’s a total hitter, I think he’ll deliver us ...

Bill Gates acknowledged Microsoft's $400 billion loss in the mobile market, attributing the failure to their own decisions. Android co-founder Rich Miner stated he developed Android to avoid ...

Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the ...